We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 0% above its sector, the market expects faster growth.
Tien Liang BioTech Co., Ltd., established in 1960 and headquartered in New Taipei City, Taiwan, is a pharmaceutical enterprise involved in the development, manufacturing, and global distribution of a diverse array of health and medicinal products. The company's offerings include traditional Chinese medicine (TCM) formulations, predominantly in pill form. These remedies address a broad spectrum of conditions, such as internal organ deficiencies (e.g., liver and kidney), various forms of musculoskeletal and neuropathic discomfort (including low back pain, joint pain, rheumatism, gout, and neuralgia), and common ailments like dizziness, digestive issues (constipation, hemorrhoids), respiratory symptoms (colds, bronchitis, coughs), and skin conditions (athlete's foot). Additionally, Tien Liang BioTech provides a range of Western pharmaceutical products. This segment features topical applications like ointments, pain relief gels, soreness sprays, and transdermal pain patches, alongside oral preparations such as tablets and capsules. The portfolio also includes specialized items like hair removal creams. Beyond pharmaceuticals, the company extends its reach into general consumer health and personal care. These offerings comprise products designed for body relaxation and comfort, items to alleviate post-exercise discomfort, oral hygiene products, and various soaps.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 4127.TWO and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
